BLOG

endpoints

GV wagers on seasoned team’s intranasal ‘temporary’ preventative approach to viruses — with ex-Gilead CEO John Martin jumping on board

Leyden Labs will focus on respiratory viruses with potential to cause pandemics, said Wiedhaup, who’s taking up the CEO role after a career spanning academia, biotech and consulting.